Abstract
A double-blind clinical trial of clomipramine versus phenelzine was carried out on 30 patients suffering from DSM-III obsessive-compulsive disorder. The study period was 12 weeks, and the maximum doses used (from the fifth week on) were 225 mg/day for clomipramine (14 patients) and 75 mg/day for phenelzine (12 patients); four patients dropped out. Obsessive symptoms improved significantly in both drug groups, but there was no significant difference between groups. Depressive symptoms improved before obsessive ones.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Clomipramine / adverse effects
-
Clomipramine / therapeutic use*
-
Depressive Disorder / drug therapy
-
Depressive Disorder / psychology
-
Dexamethasone
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Drug Administration Schedule
-
Female
-
Humans
-
Hydrocortisone / blood
-
Male
-
Obsessive-Compulsive Disorder / drug therapy*
-
Obsessive-Compulsive Disorder / psychology
-
Personality Inventory
-
Phenelzine / adverse effects
-
Phenelzine / therapeutic use*
Substances
-
Dexamethasone
-
Clomipramine
-
Phenelzine
-
Hydrocortisone